Rigel Pharmaceuticals (RIGL) Debt Ratio (2019 - 2026)

Rigel Pharmaceuticals' Debt Ratio history runs 8 years deep, the most recent figure standing at 0.09 for Q1 2026.

• On a quarterly basis, Debt Ratio fell 73.82% year-over-year to 0.09 in Q1 2026; TTM through Mar 2026 was 0.09, a 73.82% decrease from a year earlier, with the FY2025 full-year figure at 0.16, down 60.85% from the prior year.
• Debt Ratio declined to 0.09 in Q1 2026 per RIGL's latest filing, from 0.16 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.52 in Q3 2023 and bottomed at 0.09 in Q1 2026.
• The 5-year median for Debt Ratio is 0.34 (2022), against an average of 0.35.
• Across the five-year window, Debt Ratio soared 220.19% in 2022 and plunged 73.82% in 2026, its largest moves.
• Year by year, Debt Ratio stood at 0.29 in 2022, then soared by 73.07% to 0.51 in 2023, then fell by 19.69% to 0.41 in 2024, then plunged by 60.85% to 0.16 in 2025, then sank by 44.4% to 0.09 in 2026.
• Per Business Quant, the three latest RIGL Debt Ratio figures stand at 0.09 (Q1 2026), 0.16 (Q4 2025), and 0.25 (Q3 2025).